Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Genoptix, Inc. (NASDAQ:GXDX) in connection with their efforts to sell the company to Novartis AG (NYSE:NVS). If the transaction is completed, Genoptix shareholders will receive $25.00 in cash for each share of Genoptix common stock they hold. The transaction is expected to close in the first half of 2011.

Robbins Umeda LLP's investigation concerns whether the Genoptix board undertook a fair process to obtain fair consideration for its shareholders. Specifically, the investigation concerns whether members of the Genoptix board breached their fiduciary duties to its shareholders by failing to adequately shop the company before entering into the transaction with Novartis.

If you are a shareholder of Genoptix, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at info@robbinsumeda.com.

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights lawyers. Robbins Umeda LLP has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.

Attorney Advertising. Past results do not guarantee a similar outcome. We invite you to contact us today to discuss your case.

Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Genoptix, Inc. (MM).
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Genoptix, Inc. (MM).